Transmedics Group shares rise 1.15% premarket after Stifel initiates coverage at Neutral.

Transmedics Group, Inc. rose 1.15% in premarket trading, with Stifel initiating coverage on the company at Neutral with a $115 price target. TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation.